Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06223373 · ClinicalTrials.gov registry record · NA
Blood Flow Restriction Therapy Following Acute Shoulder Injury Patients
A NA study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT06223373: Clinical Trial NA study, sponsored by Wake Forest University Health Sciences.
NCT06223373 is a NA study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06223373, a NA study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
Atrophy and weakness of the shoulder are a common problem following treatment of a number of shoulder and elbow pathologies. Even with relatively short periods of reduced activity, the magnitude of muscle loss can be quite substantial.
Primary Outcome
measuring shoulder strength in injured and non-injured arms for both study groups using a Biodex testing machine - Low Score indicates low torque/strength, high score indicates high torque/strength
Interventions
- DEVICE Blood Flow Restriction
- DEVICE "sham" Blood Flow Restriction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-04-13 |
| Est. Completion | 2024-10-18 |
| Phase | NA |
Why NCT06223373 stopped before completion
NCT06223373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Blood Flow Restriction is the first listed.
NCT06223373 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06223373 about?
NCT06223373 is a clinical study titled "Blood Flow Restriction Therapy Following Acute Shoulder Injury Patients". Atrophy and weakness of the shoulder are a common problem following treatment of a number of shoulder and elbow pathologies. Even with relatively short periods of reduced activity, the magnitude of muscle loss can be quite substantial.
What is the current status of trial NCT06223373?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2024-04-13. Estimated completion is 2024-10-18.
What interventions are being tested in trial NCT06223373?
The interventions under investigation include: Blood Flow Restriction (DEVICE), "sham" Blood Flow Restriction (DEVICE).
Who is sponsoring clinical trial NCT06223373?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06223373's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI